Marianne Stanford, PhD | Source | Vice President Research & Development at IMV

Now we do the next step, which is get the vaccine ready for delivery into people. We do the safety studies and the studies that really moves us from pre-clinical, into clinical. If the vaccine is proven to be safe and effective, you move quickly into the next phase of clinical study and then everything will hopefully be data driven from there.